Pharmacokinetics and safety of BCX9250, an ALK2 inhibitor for the potential treatment of Fibrodysplasia Ossificans Progressiva, following single and multiple doses of BCX9250 in healthy subjects

Matthew Davidson, Eniko Nagy, Krithika Praveen,Ys Babu, William Sheriden,Carlos Sanabria,Diane Gesty-Palmer

JOURNAL OF BONE AND MINERAL RESEARCH(2023)

引用 0|浏览1
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要